Key result
DES reduce in-stent restenosis to <10% compared to 15-30% with bare-metal stents.
Why the study?
Despite drug-eluting stents reducing in-stent restenosis, restenosis remains a concern and no device has demonstrated clear superiority, leaving the ideal treatment method uncertain.
How do different generations and compositions of drug-eluting stents and novel coronary devices compare in terms of safety and efficacy for patients undergoing percutaneous coronary intervention?
How do different generations and compositions of drug-eluting stents and novel coronary devices compare in terms of safety and efficacy for patients undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
This narrative review highlights that while modern drug-eluting stents have reduced in-stent restenosis to under 10% and largely show non-inferiority among current designs, overcoming remaining late events may require a personalized approach combining newer technologies like drug-coated balloons and bioadaptors.
Coronary artery disease is the most common cause of mortality worldwide. Percutaneous coronary intervention represents an important method of treatment. Over time, the methods have been refined to improve safety and efficacy. With the development of drug-eluting stents, in-stent restenosis has importantly decreased, but it remains a relevant concern in terms of the need for additional revascularization procedures or recurrent coronary events. Different platforms, polymers, and anti-proliferative agents have been tested, mostly demonstrating non-inferiority when compared. Additional devices, such as drug-coated balloons, bioresorbable scaffold systems, gene-eluting stents and bioadaptor implants have been developed. As none of the aforementioned methods demonstrated considerable superiority over the others, the search for the ideal treatment method continues. Based on currently available data, the ideal treatment method could be a personalized approach combining different revascularization methods. Additional research with subpopulation group studies, different associated diseases or vessels affected, and longer follow-up are required to determine better subgroups of patients that would benefit most from specific treatment methods.
No takes yet. Share an insight, caveat, or question.
Arh et al. (2025) conducted a review in Coronary artery disease undergoing percutaneous coronary intervention. Drug-eluting stents (various platforms, polymers, and anti-proliferative agents) and novel revascularization devices (drug-coated balloons, bioresorbable scaffolds, gene-eluting stents, bioadaptor implants) vs. Bare-metal stents and alternative generations/types of drug-eluting stents was evaluated on In-stent restenosis, target lesion failure, target vessel failure, and stent thrombosis. Drug-eluting stents reduce in-stent restenosis to less than 10% compared to 15-30% with bare-metal stents, with most contemporary DES platforms demonstrating non-inferiority to one another.
Synapse has enriched 10 related papers. Consider them for comparative context: